Impact of T-cell Affinity in Bispecific Therapy in R/R MM

Investigators plan to present detailed findings from the MajesTEC-3 study at a future medical conference and share them with regulatory authorities.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Patients with multiple myeloma who received palonosetron, dexamethasone, aprepitant, and olanzapine achieved a 44.1% CR rate across all study phases.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Treatment with anito-cel shows a predictable and manageable safety profile among those with relapsed/refractory multiple myeloma in the iMMagine-1 trial.

Karen Kehl shares her decade-long journey with multiple myeloma, discussing treatment options and the impact of bispecific antibodies like talquetamab with Binod Dhakal, MD.